Is Adeshwar Meditex overvalued or undervalued?

As of 6 November 2025, Adeshwar Meditex's valuation grade has moved from fair to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 13.41, an EV to EBITDA of 8.56, and a PEG ratio of 4.49, which indicates that the stock may not justify its current price based on its earnings growth potential.
In comparison to its peers, Adeshwar Meditex's PE ratio is significantly lower than that of Poly Medicure, which has a PE of 53.88, and Blue Jet Health, with a PE of 27.66, both categorized as very expensive. The company's recent stock performance has been underwhelming, with a year-to-date return of -26.04%, contrasting sharply with the Sensex's gain of 6.62% during the same period, reinforcing the notion that the stock is overvalued.